Portland, OR Clinical Trials Report — April 2026

For Portland residents considering clinical research, April 2026 presents a critical window for those looking to join trials before enrollment concludes. A total of 50 clinical trials are slated to close within the next 90 days, with 2 of these still actively seeking healthy volunteers. This urgency is particularly relevant for individuals without specific health conditions who are interested in contributing to medical advancements.

New Opportunities in Portland Research

This month, Portland saw the opening of 10 new clinical trials, an increase from the 7 trials that launched in March 2026. This brings the total number of recruiting trials in Portland to 991 across 332 research facilities. These new studies offer diverse opportunities, including significant Phase 2 and Phase 3 trials from major sponsors, providing participants access to cutting-edge research.

Notable new trials include:

• Incyte Corporation is sponsoring NCT07522073, a Phase 3 study evaluating chemotherapy with or without INCB161734 in previously untreated, KRAS G12D-mutated metastatic pancreatic ductal adenocarcinoma. This trial aims to enroll 588 participants to assess the efficacy and safety of this combination therapy.
• Novo Nordisk A/S is initiating NCT07509307, "AMAZE 6," a Phase 3 research study investigating the medicine NNC0487-0111. This trial seeks 400 participants with excess body weight and knee osteoarthritis to evaluate how well the medicine helps with weight loss and pain reduction, compared to a placebo, administered as weekly injections.
• Priovant Therapeutics, Inc. is launching NCT07532603, a Phase 2/3 study of brepocitinib in adults with lichen planopilaris. This study will evaluate the clinical safety and efficacy of oral brepocitinib in 342 participants.
• The OHSU Knight Cancer Institute is sponsoring NCT07511504, a Phase 2 trial testing Y-90 radioembolization, durvalumab, tremelimumab, and zanzalintinib for the treatment of unresectable and locally-advanced hepatocellular carcinoma. This study plans for 40 participants.
• Legacy Health System is leading NCT07506876, a Phase 2 study on concurrent neoadjuvant chemo/endocrine therapy in HER2+ breast cancer. This trial, involving 30 participants, aims to see if adding endocrine therapy to standard chemotherapy and HER2-directed therapy improves outcomes.

New trials this month are exploring conditions such as acute myeloid leukemia, breast cancer (including infiltrating ductal carcinoma and HER-2 positive), concussion/mild traumatic brain injury, lichen planopilaris, locally advanced hepatocellular carcinoma, obesity, and studies for neonates or premature babies. Drug trials represent the majority of new studies, with 6 new drug trials, followed by 5 other trial types, 2 procedure trials, 1 behavioral trial, and 1 biological trial.

Opportunities for Healthy Volunteers

While only 0 of the 10 new trials opened this month are accepting healthy volunteers, there are still significant opportunities for individuals without specific medical conditions to contribute to research in Portland. A total of 76 clinical trials are currently recruiting healthy participants across the city, providing numerous avenues for those interested in supporting medical science.

Leading Research Facilities in Portland

Portland is home to several prominent research institutions that consistently conduct a high volume of clinical trials. These facilities are key destinations for individuals seeking to participate in medical research:

• Oregon Health and Science University (195 trials)
• Oregon Health & Science University (148 trials)
• Providence Portland Medical Center (121 trials)
• Providence Saint Vincent Medical Center (88 trials)
• OHSU Knight Cancer Institute (36 trials)
• Research Site (34 trials)
• Providence St. Vincent Medical Center (23 trials)
• Legacy Good Samaritan Hospital and Medical Center (23 trials)
• Oregon Health Sciences University (22 trials)
• Legacy Emanuel Children's Hospital (18 trials)
• Kaiser Permanente Northwest (18 trials)
• VA Portland Health Care System, Portland, OR (18 trials)

Collectively, facilities associated with Oregon Health & Science University (OHSU), including the OHSU Knight Cancer Institute, are the most active research hubs in the city, offering a broad spectrum of studies, particularly in cancer research. Providence Health & Services facilities also play a significant role in the local research landscape.

Trials Closing Soon: Act Now

For patients managing certain health conditions, several trials are nearing their enrollment deadlines. Conditions with trials closing within the next 90 days include:

• Glaucoma (2 trials)
• Advanced breast cancer (2 trials)
• Acute leukemia (2 trials)
• Acute undifferentiated leukemia (1 trial)
• Anatomic stage iii breast cancer ajcc v8 (1 trial)
• Aortic aneurysm, abdominal (1 trial)
• Acute myeloid leukemia (1 trial)
• ALS-frontotemporal dementia (1 trial)
• Amyotrophic lateral sclerosis (1 trial)
• Anatomic stage ii breast cancer ajcc v8 (1 trial)

Individuals with these conditions should explore these options promptly to avoid missing opportunities to participate.

Expanding Your Search: Nearby Cities

While Portland offers a robust selection of clinical trial opportunities, individuals may also find options in nearby communities within Oregon. Cities with active trials include Eugene (2 trials), Gresham (1 trial), and Tualatin (1 trial).

Who Can Participate?

Participation in clinical trials is open to a diverse range of individuals. Of the 10 new trials launched this month, 9 include older adults, ensuring that senior populations have ample opportunity to contribute to medical science. Additionally, 1 new trial is specifically designed for male participants, and 1 includes children. Academic institutions like Oregon Health and Science University and the OHSU Knight Cancer Institute, alongside industry sponsors such as Incyte Corporation, Novo Nordisk A/S, and Priovant Therapeutics, Inc., are driving significant research efforts in Portland.

As we move through April, the focus will remain on the ongoing enrollment in these significant Phase 2 and 3 trials and the continued exploration of new therapeutic strategies, with Portland's robust research community at the forefront of medical innovation.